Thursday, January 24, 2019 5:44:16 PM
This study was published online yesterday from the The Annals of Thoracic Surgery. An analysis of 55 patients that underwent emergency open-heart operations that were at high risk of bleeding due to treatment with coagulation-active substances (emphasis mine).
It's results like this will get a lot of attention!
Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding
https://www.sciencedirect.com/science/article/pii/S000349751930102X?dgcid=rss_sd_all
Abstract
Background
To analyze the results of Cytosorb adsorption (CytoSorbents Inc., USA) during emergency open-heart operations in patients at high risk of bleeding due to treatment with coagulation-active substances.
Methods
We investigated 55 consecutive patients (median age 70 [IQR 60,77] years) who underwent emergency cardiac surgery at our institution between June 2016 and June 2018. All patients were on therapy with either Ticagrelor (n=43) or Rivaroxaban (n=12). In 39 of 55 cases, we routinely installed standardized Cytosorb adsorption into the heart-lung-machine (CA-group). Bleeding complications during and after surgery were analyzed in detail and compared to eight patients without adsorption (WA-group
Results
In CA-group (Cytosorb) no re-thoracotomies had to be performed. Drainage volumes over 24-hours were only 350 [IQR 300,450] ml after Ticagrelor administration and 390 [IQR 310,430] ml after Rivaroxaban therapy. In the majority of patients, transfusions of blood products were not needed. Compared to this, among the WA-group patients, multiple bleeding complications occurred. These were associated with longer total operation (p=0.0042), higher drainage volumes (p=0.0037), more transfusions of red blood cells (p=0.0119) and transfusion of platelet (p=0.0475), a significantly higher re-thoracotomy rate (p=0.0003), significantly prolonged retention in the intensive care unit (p=0.0141) and a longer hospital stay (p=0.0244).
Conclusions
The intra-operative use of Cytosorb adsorption of Ticagrelor and Rivaroxaban in emergency open-heart operations is reported for the first time. The data show that the strategy is safe and an effective method to reduce bleeding complications. We recommend the use for safety in patients with Ticagrelor or Rivaroxaban undergoing emergency cardiac surgery.
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM